{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:12:33Z","timestamp":1765825953868,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010114","name":"Yrj\u00f6 Jahnssonin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010114","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Parkinson foundation Medical Research Center Oulu"},{"name":"Oulu University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several heterozygous variants of the glucocerebrosidase gene (<jats:italic>GBA1<\/jats:italic>) have been reported to increase the risk of Parkinson\u2019s disease (PD) and dementia with Lewy bodies (DLB). <jats:italic>GBA1<\/jats:italic>-associated PD has been reported to be more severe than idiopathic PD, and more deleterious variants are associated with more severe clinical phenotypes. We report a family with a heterozygous p.Pro454Leu variant in <jats:italic>GBA1<\/jats:italic>. The variant was associated with a severe and rapidly progressive neurodegenerative disease with Lewy bodies that were clinically and pathologically diverse. Pathogenicity prediction algorithms and evolutionary analyses suggested that p.Pro454Leu is deleterious.<\/jats:p>","DOI":"10.1038\/s41531-023-00501-4","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:12:13Z","timestamp":1680682333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0183-9054","authenticated-orcid":false,"given":"Jussi O. T.","family":"Sipil\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-5646","authenticated-orcid":false,"given":"Laura","family":"Kyt\u00f6vuori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuomas","family":"Rauramaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Rauhamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3446-7093","authenticated-orcid":false,"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-3791","authenticated-orcid":false,"given":"Kari","family":"Majamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"501_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3233\/JPD-171092","volume":"7","author":"G O\u2019Regan","year":"2017","unstructured":"O\u2019Regan, G., deSouza, R. M., Balestrino, R. & Schapira, A. H. Glucocerebrosidase mutations in Parkinson disease. J. Parkinsons Dis. 7, 411\u2013422 (2017).","journal-title":"J. Parkinsons Dis."},{"key":"501_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.nbd.2016.06.004","volume":"94","author":"JT Geiger","year":"2016","unstructured":"Geiger, J. T. et al. Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiol. Dis. 94, 55\u201362 (2016).","journal-title":"Neurobiol. Dis."},{"key":"501_CR3","doi-asserted-by":"publisher","first-page":"e200002","DOI":"10.1212\/NXG.0000000000200002","volume":"8","author":"EJ Hill","year":"2022","unstructured":"Hill, E. J. et al. Genome sequencing in the Parkinson disease clinic. Neurol. Genet. 8, e200002 (2022).","journal-title":"Neurol. Genet."},{"key":"501_CR4","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/mds.28195","volume":"35","author":"S Petrucci","year":"2020","unstructured":"Petrucci, S. et al. GBA-related Parkinson\u2019s disease: dissection of genotype-phenotype correlates in a large italian cohort. Mov. Disord. 35, 2106\u20132111 (2020).","journal-title":"Mov. Disord."},{"key":"501_CR5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jnnp-2020-322857","volume":"91","author":"TB Stoker","year":"2020","unstructured":"Stoker, T. B. et al. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 91, 695\u2013702 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"501_CR6","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/mds.28112","volume":"35","author":"JM den Heijer","year":"2020","unstructured":"den Heijer, J. M. et al. A large-scale Full GBA1 gene screening in Parkinson\u2019s disease in the Netherlands. Mov. Disord. 35, 1667\u20131674 (2020).","journal-title":"Mov. Disord."},{"key":"501_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3389\/fneur.2020.00527","volume":"11","author":"DA Olszewska","year":"2020","unstructured":"Olszewska, D. A. et al. Association between glucocerebrosidase mutations and Parkinson\u2019s disease in Ireland. Front Neurol. 11, 527 (2020).","journal-title":"Front Neurol."},{"key":"501_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-016-0097-0","volume":"11","author":"BA Benitez","year":"2016","unstructured":"Benitez, B. A. et al. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson\u2019s Disease. Mol. Neurodegener. 11, 29 (2016).","journal-title":"Mol. Neurodegener."},{"key":"501_CR9","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-022-02511-7","volume":"129","author":"G H\u00f6glinger","year":"2022","unstructured":"H\u00f6glinger, G. et al. GBA-associated PD: chances and obstacles for targeted treatment strategies. J. Neural Transm. 129, 1219\u20131233 (2022).","journal-title":"J. Neural Transm."},{"key":"501_CR10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/mds.27490","volume":"33","author":"A Thaler","year":"2018","unstructured":"Thaler, A. et al. Survival rates among Parkinson\u2019s disease patients who carry mutations in the LRRK2 and GBA genes. Mov. Disord. 33, 1656\u20131660 (2018).","journal-title":"Mov. Disord."},{"key":"501_CR11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/mds.27989","volume":"35","author":"T Simuni","year":"2020","unstructured":"Simuni, T. et al. Clinical and dopamine transporter imaging characteristics of leucine rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson\u2019s disease participants in the Parkinson\u2019s progression markers initiative: a cross-sectional study. Mov. Disord. 35, 833\u2013844 (2020).","journal-title":"Mov. Disord."},{"key":"501_CR12","doi-asserted-by":"publisher","first-page":"935.e3","DOI":"10.1016\/j.neurobiolaging.2013.09.019","volume":"35","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Clinicogenetic study of GBA mutations in patients with familial Parkinson\u2019s disease. Neurobiol. Aging 35, 935.e3\u20138 (2014).","journal-title":"Neurobiol. Aging"},{"key":"501_CR13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.3233\/JPD-212657","volume":"11","author":"J Maple-Gr\u00f8dem","year":"2021","unstructured":"Maple-Gr\u00f8dem, J. et al. Lack of association between GBA mutations and motor complications in European and American Parkinson\u2019s disease cohorts. J. Parkinsons Dis. 11, 1569\u20131578 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"501_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","volume":"120","author":"O Goker-Alpan","year":"2010","unstructured":"Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I. & Sidransky, E. Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol. 120, 641\u2013649 (2010).","journal-title":"Acta Neuropathol."},{"key":"501_CR15","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","volume":"32","author":"SA Schneider","year":"2017","unstructured":"Schneider, S. A. & Alcalay, R. N. Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature. Mov. Disord. 32, 1504\u20131523 (2017).","journal-title":"Mov. Disord."},{"key":"501_CR16","first-page":"365","volume":"44","author":"M Wigderson","year":"1989","unstructured":"Wigderson, M. et al. Characterization of mutations in Gaucher patients by cDNA cloning. Am. J. Hum. Genet. 44, 365\u2013377 (1989).","journal-title":"Am. J. Hum. Genet."},{"key":"501_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30843-6","volume":"8","author":"AR Winslow","year":"2018","unstructured":"Winslow, A. R. et al. Self-report data as a tool for subtype identification in genetically-defined Parkinson\u2019s Disease. Sci. Rep. 8, 12992 (2018).","journal-title":"Sci. Rep."},{"key":"501_CR18","doi-asserted-by":"publisher","first-page":"e1003440","DOI":"10.1371\/journal.pcbi.1003440","volume":"10","author":"J Bendl","year":"2014","unstructured":"Bendl, J. et al. PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. PLoS Comput Biol. 10, e1003440 (2014).","journal-title":"PLoS Comput Biol."},{"key":"501_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"501_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/mds.26071","volume":"30","author":"K Brockmann","year":"2015","unstructured":"Brockmann, K. et al. GBA-associated Parkinson\u2019s disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord. 30, 407\u2013411 (2015).","journal-title":"Mov. Disord."},{"key":"501_CR21","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"501_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","volume":"80","author":"R Cilia","year":"2016","unstructured":"Cilia, R. et al. Survival and dementia in GBA-associated Parkinson\u2019s disease: The mutation matters. Ann. Neurol. 80, 662\u2013673 (2016).","journal-title":"Ann. Neurol."},{"key":"501_CR23","unstructured":"Graybiel, A. M., Mink, J. W. in The Cognitive Neurosciences (eds. Gazzaniga, M. S., et al.) p565\u2013p585 (Massachusetts Institute of Technology, 2009)."},{"key":"501_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ymgme.2011.04.015","volume":"103","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen, L. et al. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson\u2019s disease. Mol. Genet. Metab. 103, 410\u2013412 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"501_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/ene.13395","volume":"24","author":"CH Adler","year":"2017","unstructured":"Adler, C. H. et al. GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur. J. Neurol. 24, 1363\u20131368 (2017).","journal-title":"Eur. J. Neurol."},{"key":"501_CR26","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/brain\/awm142","volume":"130","author":"PA Kempster","year":"2007","unstructured":"Kempster, P. A. et al. Patterns of levodopa response in Parkinson\u2019s disease: a Clinic-pathological study. Brain 130, 2123\u20132128 (2007).","journal-title":"Brain"},{"key":"501_CR27","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/mds.28406","volume":"36","author":"WRW Martin","year":"2021","unstructured":"Martin, W. R. W. et al. Is levodopa response a valid indicator of Parkinson\u2019s disease? Mov. Disord. 36, 948\u2013954 (2021).","journal-title":"Mov. Disord."},{"key":"501_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/mdc3.12885","volume":"7","author":"V Pitz","year":"2020","unstructured":"Pitz, V. et al. The levodopa response varies in pathologically confirmed Parkinson\u2019s disease: a systematic review. Mov. Disord. Clin. Pr. 7, 218\u2013222 (2020).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"501_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41531-021-00273-9","volume":"8","author":"K Men\u0161\u00edkov\u00e1","year":"2022","unstructured":"Men\u0161\u00edkov\u00e1, K. et al. Lewy body disease or diseases with Lewy bodies? NPJ Parkinsons Dis. 8, 3 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"501_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.parkreldis.2018.05.009","volume":"55","author":"A Thaler","year":"2018","unstructured":"Thaler, A. et al. Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat. Disord. 55, 45\u201349 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"501_CR31","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","volume":"14","author":"I Ron","year":"2005","unstructured":"Ron, I. & Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387\u20132398 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"501_CR32","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1016\/S0021-9258(19)67845-2","volume":"266","author":"T Ohashi","year":"1991","unstructured":"Ohashi, T. et al. Characterization of human glucocerebrosidase from different mutant alleles. J. Biol. Chem. 266, 3661\u20133667 (1991).","journal-title":"J. Biol. Chem."},{"key":"501_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.28792","volume":"37","author":"N Omer","year":"2022","unstructured":"Omer, N. et al. Glucocerebrosidase activity is not associated with parkinson\u2019s disease risk or severity. Mov. Disord. 37, 190\u2013195 (2022).","journal-title":"Mov. Disord."},{"key":"501_CR34","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/mds.28144","volume":"35","author":"W Schierding","year":"2020","unstructured":"Schierding, W. et al. Common variants coregulate expression of GBA and modifier genes to delay Parkinson\u2019s disease onset. Mov. Disord. 35, 1346\u20131356 (2020).","journal-title":"Mov. Disord."},{"key":"501_CR35","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","volume":"131","author":"D Reczek","year":"2007","unstructured":"Reczek, D. et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell 131, 770\u2013783 (2007).","journal-title":"Cell"},{"key":"501_CR36","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/mds.103","volume":"33","author":"C Blauwendraat","year":"2018","unstructured":"Blauwendraat, C. et al. Coding variation in GBA explains the majority of the SYT11-GBA Parkinson\u2019s disease GWAS locus. Mov. Disord. 33, 1821\u20131823 (2018).","journal-title":"Mov. Disord."},{"key":"501_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ymgme.2011.07.002","volume":"104","author":"M Horowitz","year":"2011","unstructured":"Horowitz, M., Pasmanik-Chor, M., Ron, I. & Kolodny, E. H. The enigma of the E326K mutation in acid \u03b2-glucocerebrosidase. Mol. Genet. Metab. 104, 35\u201338 (2011).","journal-title":"Mol. Genet. Metab."},{"key":"501_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ymgme.2019.10.001","volume":"128","author":"O Goldstein","year":"2019","unstructured":"Goldstein, O. et al. Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson\u2019s disease risk? Mol. Genet. Metab. 128, 470\u2013475 (2019).","journal-title":"Mol. Genet. Metab."},{"key":"501_CR39","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/mds.28225","volume":"35","author":"A Greuel","year":"2020","unstructured":"Greuel, A. et al. GBA Variants in Parkinson\u2019s Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Mov. Disord. 35, 2201\u20132210 (2020).","journal-title":"Mov. Disord."},{"key":"501_CR40","doi-asserted-by":"publisher","first-page":"195.e7","DOI":"10.1016\/j.neurobiolaging.2017.01.019","volume":"53","author":"A Siitonen","year":"2017","unstructured":"Siitonen, A. et al. Genetics of early-onset Parkinson\u2019s disease in Finland: exome sequencing and genome-wide association study. Neurobiol. Aging 53, 195.e7\u2013195.e10 (2017).","journal-title":"Neurobiol. Aging"},{"key":"501_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 19, 170\u2013178 (2020).","journal-title":"Lancet Neurol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00501-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00501-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:20:12Z","timestamp":1680682812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00501-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["501"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00501-4","relation":{},"ISSN":["2373-8057"],"issn-type":[{"type":"electronic","value":"2373-8057"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}